CD274 and non-small cell lung carcinoma: Kim et al. conducted a phase 1/2a trial of autologous NK cells plus pembrolizumab vs. pembrolizumab monotherapy in patients with advanced NSCLC who had previously failed platinum-based chemotherapy and had a PD-L1 tumor score of at least 1% [141].